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Background: Intrahepatic cholangiocarcinoma (IHCC) is the second most frequent primary malignant liver tumor
following hepatocellular carcinoma. It is a highly fatal disease and has few therapeutics. The CXC chemokine ligand-12
(CXCL12)/CXC chemokine receptor type 4 (CXCR4) axis has been shown to be involved in tumorgenesis, proliferation,
and angiogenesis in a variety of cancers including IHCC. However, its prognostic significance in IHCC is unclear. The
purpose of this study was to examine the functional role of CXCR4 in the progression and metastasis of IHCC and
explore the underlying mechanism.
Methods: The CXCR4 expression, overall survival, and the clinical characteristics including age, sex, differentiation
degree, tumor size, vascular invasion, lymph node metastasis, TNM stage, and T stage were analyzed for 122 IHCC
patients. Short hairpin RNA (shRNA) against CXCR4 was used to disrupt the CXCL12/CXCR4 signal transduction
pathways in IHCC cell lines. In vitro assays, including CCK-8 assay, flow cytometry, and colony formation assay, and
in vivo tumor formation assay were utilized to detect the cell phenotype of CXCR4 knockdown cells. Transwell and
wound healing assays were used to examine the IHCC cell invasion and migration ability. The Wnt pathway was
assessed by Western blot and β-Catenin/Tcf transcription reporter assay.
Results: We demonstrated that CXCR4 expression was closely correlated with IHCC progression and metastasis
characteristics. The overall survival of patients with high CXCR4 expression was significantly lower than that of patients
with low CXCR4 expression. Furthermore, we showed that the abrogation of CXCR4 had significantly negative
influence on the IHCC cell phenotype, including in vitro cell proliferation, cell cycle, colony formation, cell invasion, and
in vivo tumorigenicity. In addition, CXCR4 knockdown downregulated Wnt target genes and mesenchymal markers
such as Vimentin and Slug.
Conclusions: In conclusion, our result shows that high CXCR4 expression is associated with IHCC progression and
metastasis via the canonical Wnt pathway, suggesting that CXCR4 may serve as a promising therapeutic target for
IHCC.
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Intrahepatic cholangiocarcinoma (IHCC) is a malignancy
whose pathogenesis involves abnormal biliary epithelial
differentiation [1]. It is the most frequent primary malig-
nant liver tumor next to hepatocellular carcinoma and is
highly fatal because of its early invasion, widespread me-
tastasis, and the lack of an effective therapy [2,3]. There-
fore, it is urgent to uncover the molecular mechanisms of
IHCC and identify potential therapeutic targets to im-
prove the treatment. Chemokine receptors form a large
family of proteins that mediate chemotaxis of cells to-
wards a gradient of chemokines. Many studies have shown
that chemokines and their receptors are implicated in the
development of different types of cancers [4-6]. One of
the best studied chemokine receptors is CXCR4. CXCR4
is a G protein-coupled chemokine receptor, encoded on
chromosome 2 [7]. During embryonic development,
CXCR4 is expressed on progenitor cells, allowing the
migration from their birthplace to their final destination
where they will differentiate into organs and tissues. In the
late 1990s, CXCR4 expressed on CD4+ T cells was found
to serve as a co-entry receptor for human immunodefi-
ciency virus HIV-1 [8]. The following-up studies also
found that CXCR4 can mediate the metastasis of a variety
of cancers [4,6,9,10]. CXCR4 selectively binds the CXC
chemokine ligand-12 (CXCL12, or SDF-1), which has
been found to be important in the tumorigenesis, prolifer-
ation, metastasis, and angiogenesis in cancers [11,12].
CXCR4 has been reported to be upregulated in more than
20 cancers, including ovarian [13], prostate [14], esopha-
geal [15], melanoma [16], neuroblastoma [17], and renal
cell carcinoma [18], and plays an important role in the
communication of cancer cells with their microenviron-
ment [19,20]. Moreover, CXCR4-positive cancer cells can
migrate toward distant organs in response to CXCL12
gradient. By inhibition of CXCR4, the growth and invasion
of cancer cells can be impaired [21-23]. In 2014, T. Yu
et al. [24] found that suppressing expression of CXCR4 by
MicroRNA-9 could inhibit the proliferation of oral squa-
mous cell carcinoma cells both in vitro and in vivo
through the Wnt/β-catenin signaling pathway, and activa-
tion of CXCR4 expression led to the constitutive activation
of β-catenin, implying the important role of Wnt/β-catenin
in CXCR4 signaling, which was consistent with the previ-
ous reports in colorectal cancer [25], ovarian cancer [26],
pancreatic cancer [23], and bone marrow stromal cells [27].
In cholangiocarcinoma, Ohira et al. [28] demonstrated
that CXCR4 was mainly expressed in IHCC cells and
CXCL12 in stromal fibroblasts, and the interaction of
CXCL12 released from fibroblasts and CXCR4 expressed
on IHCC cells may be actively involved in IHCC migration,
suggesting CXCR4 could be a therapeutic target to prevent
IHCC invasion. This possibility was confirmed by Gentilini
et al. [29] using AMD3100, a non-peptide antagonist of theCXCR4, and Tan et al. [30] using siRNA targeting at
CXCR4. In 2012, CXCL12/CXCR4 was further reported to
mediate angiotensin II-enhanced epithelial-to-mesenchymal
transition (EMT) in IHCC [31]. More recently, Leelawat K.
et al. [4] found that CD24 could induce CXCR4 expression
in cholangiocarcimoma cells, which may assist invasion of
the cancer cells. When treated by AMD3100, the motility
and invasiveness of CD24 (+) cells were decreased, implying
the importance of CXCR4 in cholangiocarcinoma cell inva-
sion. However, the precise function of CXCR4 and the signal
transduction pathways following CXCR4 activation in IHCC
remain elusive. The aim of this study was to define the




Human intrahepatic cholangiocarcinoma cell lines, HuC
CT1 (ATCC, Manassas, VA, USA), HCCC-9810 ( Keygen
Biotech, China), RBE ( Keygen Biotech, China), and Huh28
(Keygen Biotech, China) were cultured at 37°C in RPMI
1640 medium (Hyclone) supplemented with 10% fetal calf
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin in
humidified atmosphere containing 5% CO2.
Immunohistochemistry
Samples including 122 primary IHCCs, 75 matched meta-
static lymph nodes, and 122 adjacent non-cancerous liver
tissues containing normal intrahepatic bile ducts (at least
5 cm distant from the tumor edge) were obtained from
the Department of Pathology, Shandong Provincial
Hospital. Immunohistochemical staining for CXCR4 was
performed using the SABC kit (Boster, Wuhan, China) ac-
cording to the manufacturer’s instruction. Primary anti-
body for CXCR4 (1:50, polyclonal, Abcam, MA, USA) was
used for overnight incubation at 4°C. For the evaluation of
CXCR4 IHC staining, a semi-quantitative scoring criterion
was used, in which both the staining intensity and positive
areas were recorded. A staining index (values 0–12), ob-
tained as the intensity of CXCR4-positive staining (weak,
1; moderate, 2; strong, 3) and the proportion of immune-
positive cells of interest (0%, 0; <10%, 1; 10–50%, 2; 51–
80%, 3; >80%, 4), were calculated. The cases were grouped
into low (score 0–6) and high (scores 8–12) CXCR4 ex-
pression. The study was approved by the Ethics Commit-
tee of Shandong Provincial Hospital Affiliated to
Shandong University, as stipulated by the Declaration of
Helsinki, with written informed consent for the use of the
specimens from all enrolled patients.
Construction and transfection of CXCR4 shRNAs
This study utilized three CXCR4 shRNA targeting differ-
ent regions of the CXCR4 [GenBank: NM_003467]. The
shCXCR4-1 targeted CXCR4 mRNA at nucleotides 1093-
Zhao et al. Journal of Experimental & Clinical Cancer Research 2014, 33:103 Page 3 of 12
http://www.jeccr.com/content/33/1/1031111 with sense: 5′- AGCGAGGTGGAC ATTCATC-3′,
and antisense: 5′- GATGAATGTCCACCTCGCT -3′; The
shCXCR4-2 targeted CXCR4 mRNA at nucleotides 741-
759 with sense: 5′- CTGTCCTGCTATTGCATTA -3′, and
antisense: 5′- TGACAGGACGACGATAACGTAAT -3′;
The shCXCR4-3 was designed to be homologous to nucle-
otides 206-224 of the human CXCR4 with sense: 5′-TGA-
GAAGCATGACGGACAA-3′, antisense: 5′-TTGTCCGT
CATGCTTCTCA-3′ [23]. A negative control, targeting at
no region in human genome, was designed with sense: 5′-
TTCTCCGAACGTGTCACGT-3′, antisense: 5′-ACGTGA
CACGTTCGGAGAA-3′. These shRNA oligos were cloned
to lentiviral vector pLKO.1 following the instruction pro-
vided by Addgene (Boston, MA, USA). All constructs were
verified by sequencing. Stable transfections were performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions.
Quantitative real-time RT-PCR
RNA was isolated from cells and reverse-transcribed.
Real-time RT-PCR Primers specific for target genes were
as follows: CXCR4, forward 5′-GATCAGCATCGACT
CCTTCA-3′ and reverse 5′-GGCTCCAAGGAAAGC
ATAGA-3′; β-catenin, forward 5′-AAAATGGCAGTGC
GTTTAG-3′ and reverse 5′-TTTGAAGGCAGTCTGT
CGTA-3′; c-myc, forward 5′-AATGAAAAGGCCCCCAA
GGTAGTTATCC-3′ and reverse 5′-GTCGTTTCCGCA
ACAAGTCCTCTTC-3′; CD44, forward 5′-AGAAGGTG
TGGGCAGAAGAA-3′ and reverse 5′-AAATGCACCAT
TTCCTGAGA-3′; Vimentin, forward 5′-TGTCCAAA
TCGATGTGGATGTTTC-3′ and reverse 5′-TTGTAC
CATTCTTCTGCCTCCTG-3′; Slug, forward 5′-TGTT
GCAGTGAGGGCAAGAA-3′ and reverse 5′-GACCCT
GGTTGCTTCAAGGA-3′. GAPDH (forward: 5′-AACG
GGAAGCTTGTCATCAATGGAAA-3′, reverse: 5′-GCA
TCAGCAGAGGGGGCAGAG-3′) served as an internal
control. Experiments were repeated three times in du-
plicates. Relative gene expression was calculated using
the 2-ΔΔct method.
Cell proliferation and cell cycle assays
Cell proliferation was measured using a Cell Counting Kit-
8 (CCK-8) (Dojindo Molecular Technologies, Kumamoto,
Japan). Control cells or cells stably transfected with sh-
CXCR4 or negative control were seeded into 96-well plates
at 2000 cells per well and incubated overnight with or with-
out CXCL12 (R&D, MN, USA) at 100 ng/ml. Viability of
cells were measured using a Cell Counting Kit-8. Briefly,
10 μl of CCK-8 solution was added to each well after 1, 2,
3, 4 and 5 days for proliferation measurement, respectively.
In viable cells, WST-8 was metabolized producing a
chromogen that was detected at 450 nm using a Spectra
Max M2 spectrophotometer (Molecular Devices, Sunnyvale,
California, USA).For cell cycle analysis, transfected cells were cultured for
24 h, collected, fixed into 70% ethanol at -20°C for 24 h,
stained with 50 μg/ml propidium iodide (Kaiji, Nanjing,
China) and analyzed with a FACS Calibur (Epics XL-4;
Beckman Coulter, Brea, California, USA).
Colony formation assay
A quantity of 500 cells transfected with either shCXCR4 or
negative control were cultured in 6-well plates with or
without CXCL12 for 2 weeks in regular culture medium.
Colonies with more than 50 cells per colony were counted,
fixed with methanol for 15 min, and stained with
hematoxylin and eosin (H&E). All the experiments were
performed in triplicate wells and repeated at least three
times.
β-Catenin/Tcf transcription reporter assay
Briefly, 1 × 105 cells were seeded each well in a 24-well
plate before transfection with the construct of TOPflash
or FOPflash reporter plasmid (Millipore, Billerica, MA,
USA). TOPflash comprised three copies of the Tcf/Lef
sites upstream of a thymidine kinase (TK) promoter and
the Firefly luciferase gene. FOPflash comprised three
mutated copies of Tcf/Lef sites and was used as a control
for measuring nonspecific activation of the reporter. All
transfections were performed using 0.8 μg of TOPflash
or FOPflash plasmid and 2 μl of Lipofectamine 2000. To
normalize the transfection efficiency in reporter assays,
the cells were co-transfected with 0.02 μg of an internal
control reporter plasmid, containing Renilla reniformis
luciferase driven by the TK promoter. Twenty four hours
after transfection, the luciferase assay was performed
with the Dual Luciferase Assay System kit (Promega
Corp., Madison, WI, USA). Relative luciferase activity
was reported as the fold induction after normalization
for transfection efficiency.
Wound healing and matrigel invasion assays
Cells transfected with negative control or shCXCR4 were
seeded in 6-well plates and cultured. Upon reaching ap-
propriate confluence, cells were serum starved for 24 h,
and then the cell layer was scratched with a sterile plas-
tic tip, immediately washed twice with PBS, and cultured
in serum free 1640 medium with or without CXCL12 at
37°C in a humidified incubator with 5% CO2. At 24 h,
the plates were photographed under a microscope.
For invasion assay, cells were re-suspended in serum-
free medium and seeded in the top chambers of Matrigel-
coated (invasion) chambers (24-well insert, 8 μm pore,
Corning Costar Corp., Cambridge, MA, USA) at the con-
centration of 2 × 105 per 200 μl medium. The lower cham-
bers were filled with 0.5 ml of normal culture medium
with or without CXCL12 (100 ng/ml). After 24 h, the cells
on the upper surface of the membrane were removed
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face were fixed in 4% paraformaldehyde for 15 min at
room temperature, stained with hematoxylin and eosin
(H&E), and counted under the light microscopy.
Western blotting
Whole cell extracts were prepared in lysis buffer as de-
scribed previously [32]. The cell lysates were separated by
electrophoresis in 10% SDS-polyacrylamide gels, transferred
to nitrocellulose membranes, blocked in 5% nonfat milk,
and incubated with primary antibodies against CXCR4
(1:1000 dilution, Abcam), phospho-CXCR4 (1:1000 dilution,
Abcam), β-catenin (1:1000 dilution, Abcam), VimentinA
B
Figure 1 The expression of CXCR4 on intrahepatic cholangiocarcinom
tissues, ×200: a, c, e; ×400: b, d, f. negative control (a, b), low expression (c,
to cytoplasmic CXCR4 expression in 122 patients with IHCC (log-rank test),
expression groups was 20.0 (95% CI: 19.03-21.0) and 31.0 (95% CI: 25.6-36.4
expression for 4 IHCC cells (HCCC-9810, HuCCT1, RBE and Huh28). β-actin w(1:1000 dilution, Abcam), MMP-9 (1:1000 dilution, Abcam),
and β-actin (1:5000 dilution; Abcam) at 4°C overnight. After
incubation with corresponding peroxidase-conjugated sec-
ondary antibodies (1:5000 dilution, Abcam), protein bands
were detected using an enhanced chemiluminescence re-
agent (Sigma, Ronkonkoma, New York, USA).
Tumorigenicity assay in nude mice
Five to six-week-old male nude mice used in the studies
were purchased from the Institute of Zoology, Chinese
Academy of Sciences (Beijing, China). After 4 days of
acclimatization, a total of 2 × 106 IHCC cells stably trans-
fected with either sh-CXCR4 or negative control wereC
a (IHCC). (A) Immunohistochemistry staining of CXCR4 on IHCC
d), high expression (e, f); (B) Kaplan-Meier survival analysis according
P < 0.001 and the median survival time of the CXCR4 high and low
) months, respectively; (C) Western blot analysis revealed the CXCR4
as used as a loading control.
Table 1 Relationship between expression of CXCR4 and
clinicopathological features in IHCC
CXCR4 χ2 P value
Case High Low
n n % n %
Total 122 60 50.8 62 49.2
Sex 0.688 0.447
Male 81 42 51.9 39 48.1
Female 41 18 43.9 23 56.1
Age 1.625 0.254
≥60 80 36 45 44 55
<60 42 24 57.1 18 42.9
Degree of Differentiation 3.673 0.155
Well 16 5 31.3 11 68.7
Moderate 69 33 47.8 36 52.2
Poorly 37 22 59.4 15 40.6
Tumor size 0.265 0.709
<=4.0 cm 46 24 52.1 22 47.9
>4.0 cm 76 36 47.4 40 52.6
Vascular invasion 12.022 0.001
Present 66 42 63.6 24 36.4
Absent 56 18 32.1 38 67.9
CA199 6.664 0.011
≤35KU/L 53 19 34.6 34 65.4
>35KU/L 69 41 60 28 40
Lymph node metastasis 25.231 <0.001
No 47 10 21.3 37 78.7
Yes 75 50 66.7 25 33.3
TNM stage 20.443 <0.001
I and II 22 3 13.6 19 86.4
III 57 26 45.6 31 54.4
IV 43 31 72.1 12 27.9
T stage 15.937 <0.001
T1-T2 48 17 35.4 31 64.6
T3 34 13 32.4 21 67.6
T4 40 30 75 10 25
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each mouse (left: negative control cell, right: sh-CXCR4
for group A, and inversely for group B). Each group con-
tained 3 mice. The mice were killed on the 28th day after
injection. The mice were manipulated according to the
guidelines approved by the Shandong University Institu-
tional Animal Care and Use Committee (IACUC).
Statistical analysis
The data are presented as percentages of control ± SEM
or means ± SEM from multiple experiments. The statis-
tical significance between groups was determined using
the Student’s t-test. Overall survival was counted from the
first day of surgery to the date of death or the last follow-
up visit and the estimated value was calculated by the
Kaplan-Meier method and compared between groups via
the log-rank test. SPSS version 12 (SPSS Inc. Chicago, IL,
USA) software was used for all data analyses.
Results
Association of CXCR4 expression level with IHCC cancers
Immunohistochemistry staining results showed that
CXCR4 expression was detected in the cytoplasm of most
IHCC cells but not in the adjacent non-tumorous tissues.
The representative results are shown in Figure 1A. A total
of 122 IHCC cancer patients (60 with high CXCR4 ex-
pression and 62 with low CXCR4 expression) were in-
cluded in the analysis. The demographic distributions are
shown in Table 1. CXCR4 expression distribution was not
significantly different in age, sex, differentiation degree, and
tumor size groups. However, there were more high CXCR4
expression samples among patients with vascular invasion
or lymph node metastasis (63.6 and 66.7%, respectively)
than in the non-vascular invasion or lymph node metastasis
groups (32.1 and 21.3%; P = 0.001 and P < 0.001 for the two
groups, respectively). Moreover, the proportion of high
CXCR4 expression samples increased with the increased
TNM stages from 13.6% in I/II stage to 72.1% in IV group
(P < 0.001). In addition, the distribution of T stage showed
that the percentage of high expression tumors rose signifi-
cantly with increasing T stage (P < 0.001). Table 2 shows
that there was no difference in the CXCR4 expression be-
tween primary IHCC and metastasized lymph nodes, im-
plying CXCR4 expression was not affected by the different
microenvironment in these sites. These data indicated that
CXCR4 expression was significantly correlated with vascu-
lar invasion, lymph node metastasis, and the tumor node
metastasis stages, all of which are characteristics of tumor
progression and metastasis. In addition, a Kaplan-Meier
analysis showed that CXCR4 was a powerful prognostic fac-
tor for overall survival (P < 0.001) and the median survival
time of the high, low CXCR4 expression groups was 20.0
(95% CI: 19.03-21.0) and 31.0 (95% CI: 25.6-36.4) months,
respectively (Figure 1B). In vitro, CXCR4 expression wasdetected in all four IHCC cell lines and the HuCCT-1 cell
line had the highest expression, which was therefore used
in the experiments described in this study (Figure 1C).The establishment of shCXCR4
Knockdown of transcripts using shRNA is a powerful tool
to study gene function. To study the long-term growth
pattern of IHCC cells in vitro, we constructed lenti-
shCXCR4-1, -shCXCR4-2, -shCXCR4-3 and -shCXCR4-
NC (negative control vector). QT–PCR analysis showed
Table 2 Expression of CXCR4 in human intrahepatic cholangiocarcinomas and lymph node metastasis
Case n CXCR4 expression P value
High Low
n (%) n (%)
Primary intrahepatic cholangiocarcinomas 122
With nodal metastases 75 50 (66.7) 25(33.3) <0.001
Without nodal metastasis 47 10 (21.3) 37(78.7)
Intrahepatic carcinomas with nodal metastasis
Primary IHCC 75 50(66.7) 25(33.3) 0.038
Matched lymph node metastases 75 62(82.7) 13(17.3)
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mRNA expression was inhibited up to 70% in lenti-
shCXCR4-2 and -3-transfected cell lines, particularly in
lenti-shCXCR4-3 cells (P < 0.001), which was employed
in the following experiments (Figure 2A). Moreover,
the CXCR4 protein level was also downregulated
significantly in lenti-shCXCR4 compared with lenti-
shCXCR4-NC cells (Figure 2B). Notably, the decrease ofA
C
B
Figure 2 Establishment of stable CXCR4 knockdown. (A) QT–PCR analysi
expression vectors: shCXCR4-1, shCXCR4-2, shCXCR4-3, shCXCR4-NC (negative
Western blot with CXCR4 antibody of different transfected IHCC cells. β-actin
expressions2 of CXCR4 and phosphorylated CXCR4 on Serine 339 (P339-CXCR
cells. β-actin was used as a loading control.CXCR4 phosphorylation at serine 339 was observed in
lenti-shCXCR4 cells (Figure 2C).
Abrogation of CXCR4 inhibits in vitro IHCC cell
proliferation, cell cycle, and colony-forming ability, and
in vivo tumorigenicity
To confirm the inhibitory effect of CXCR4 on cell growth,
cells stably transfected with lenti-shCXCR4-3 or lenti-s of CXCR4 expression after the transfection of different CXCR4 shRNA
control) and HuCCT1, ***P < 0.001 compared with shCXCR4-NC cells; (B)
was used as a loading control; (C) Western blot showed the different
4), together with the p-CXCR4/total CXCR4 ratio (*P < 0.05) on transfected
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shCXCR4-3 cells grew slower than shCXCR4-NC cells.
Upon treatment by the CXCR4 ligand CXCL12, IHCC cell
growth was accelerated. The difference was significant on
day 4 (P < 0.05) and day 5 (P < 0.01). However, there was




Figure 3 The influence of CXCR4 knockdown on the cell phenotype. (
CXCL12 (100 ng/ml) stimulated shCXCR4-NC on days 1, 2, 3, 4, and 5; (B) D
analysis of shCXCR4 and shCXCR4-NC cells; (C) Colony assay was assessed
colony was shown in the diagram; (D) The tumor formation ability of shCX
compared with shCXCR4-NC cells.cells (Figure 3A). Analysis of cell cycle distribution by flow
cytometry demonstrated a prolonged and prominent delay
in progression from G0 to G1 phase (48.9 vs 74.8%)
together with a reduction at both S phase (48.4 vs 24.7%)
and G2-M phase (2.68 vs 0.49%). To explore the effect
of CXCR4 knockdown on tumorigenesis in vitro, weA) CCK-8 assay was analyzed for shCXCR4, shCXCR4-NC, HuCCT1 and
istribution of cell cycle phases was demonstrated by flow cytometric
to evaluate the cell colony formation ability. The count number of the
CR4 and shCXCR4-NC cells in vivo. *P < 0.05, ** P < 0.01, ***P < 0.001
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shCXCR4-3 decreased the colony formation of IHCC cells
(P < 0.01), while CXCR4 ligand CXCL12 increased it (P <
0.001) (Figure 3C). To explore the effect of CXCR4 knock-
down on tumorigenesis in vivo, shCXCR4-3 and
shCXCR4-NC cells were injected into either side of
BALB/c nude mice subcutaneously. As shown in
Figure 3D, shCXCR4-3 inhibited the tumor formation of
IHCC cells in vivo.
CXCR4 knockdown inhibits Wnt activity, Wnt downstream
genes, and the invasion-related genes
As an important pathway for gastrointestinal cancer devel-
opment, the Wnt/β-catenin pathway and tumor invasion-
associated genes have attracted great attention. The
β-catenin/Tcf transcription reporter assay has been recog-
nized as an important method for assessing Wnt pathway
activity. Because TOPflash has three TCF-binding sites, it
can be applied to measure the activation of the canonical
Wnt pathway. Our data showed that compared with the
shCXCR4-NC cells, the CXCR4 knockdown cells exhibited
decreased TOPflash activity (P < 0.01) with FOPflash activity
unchanged. Activation of CXCR4 with its ligand, CXCL12A
B
C
Figure 4 The influence of CXCR4 knockdown on Wnt target genes and in
Normalized with control reporter plasmid, the relative luciferase activity was dem
examine the change of Wnt downstream target genes expression including β-c
inhibited the expression of these genes, while CXCL12 enhanced their expressio
was used to detect β-catenin, Vimentin and MMP-9 protein expression. β-actinenhanced TOPflash activity significantly (P < 0.01) but had
no impact on FOPflash activity (Figure 4A). Moreover, QT–
PCR analysis showed that Wnt target genes such as β-
catenin, c-myc, and CD44 were decreased in shCXCR4-3
cells but increased when activated by CXCL12 (Figure 4B).
Meanwhile, the inhibition of CXCR4 resulted in decreased
expression of invasion-related genes Slug, Vimentin and
MMP-9 and activation of CXCR4 increased the expression
of these genes (Figure 4B and C). These findings suggested
that the inhibitory effect of CXCR4 in IHCC cells was medi-
ated, at least partially, through the canonical Wnt pathway.CXCR4 knockdown decreases the invasion and migration
of IHCC cancer cells
To determine the effect of CXCR4 on cancer cell invasion
and migration, Matrigel invasion and wound healing as-
says were performed. Representative staining results are
shown in Figure 5. The data demonstrated that compared
with the control cells, the migration and invasion ability
of shCXCR4-transfected cancer cells were inhibited (P <
0.001) and when activated by CXCL12, shCXCR4 cells still
showed a less obvious increase in both invasion andvasion-related genes. (A) The β-Catenin/Tcf transcription reporter assay.
onstrated. **P < 0.01 compared with NC cells; (B) QT–PCR was applied to
atenin, c-myc, CD44, Vimentin and Slug by the 2-ΔΔCt method. shCXCR4
n. *P < 0.05, **P < 0.01 compared with NC cells; (C) Western blot analysis
was used as a loading control.
AC
B
Figure 5 The abrogation of CXCR4 inhibits the invasion and migration ability of IHCC cells. (A) Representative staining figures: shCXCR4
and negative control invading cells with and without CXCL12 stimulation (100 ng/ml); (B) the diagram of the count analysis, ***P < 0.001
compared with NC cells; (C) Wound healing assay of shCXCR4 and negative control cells with or without CXCL12 stimulation (100 ng/ml).
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in IHCC cell migration and invasion, even in CXCL12 ac-
tivated cancer cells.
Discussion
Compared with other malignancies, IHCC is generally char-
acterized by strong proliferation, invasion, and early metas-
tasis. Many factors such as adhesion molecules, proteases,
cytokines, and chemokine are involved in these processes.
CXCR4 and CXCL12 play an essential role in tumor growth,
metastasis, and cancer cell-microenvironment interaction.
CXCR4 has been known to be overexpressed in more than
20 human tumor types [13-18], and CXCR4 antagonists in-
hibit tumor growth in multiple experimental orthotopic
[33,34], subcutaneous human xenografts [35,36], and trans-
genic mouse models [37]. Preclinical cancer models have re-
vealed that directed metastasis of cancer cells is mediated by
CXCR4 activation and migration of cancer cells is towards
CXCL12 expressing organs [14,35,38] while targetingCXCR4 impairs the spread of cancer cells and development
of metastasis [34,37,38]. Moreover, high levels of CXCL12
expressed by cancer cells and tumor-associated stromal cells
directly stimulate the proliferation and invasiveness of breast
cancer cells in the autocrine and paracrine manners [19].
High CXCL12 levels in the tumor attract CXCR4-positive
inflammatory, vascular and stromal cells into the tumor
mass, where they will eventually support the tumor growth
by secreting growth factors, cytokines, chemokines, and
pro-angiogenic factors [19,39]. In addition, CXCR4 positive
cancer cells can be recruited to CXCL12-rich mesenchymal
stroma niches. This recruitment mimics the homing of nor-
mal stem cells to the bone marrow [39,40], and cancer cells
homed to bone marrow reside in a microenvironment that
protects them in a CXCR4-dependent manner from chemo-
therapy [41]. In this study, we demonstrated that the overall
survival rate of IHCC patients with high CXCR4 expression
is significantly lower than those with low CXCR4 expression.
Elevated CXCR4 expression is related to vascular invasion,
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http://www.jeccr.com/content/33/1/103lymph node metastasis, and the TNM stages. This is similar
to previous reports that CXCR4 may be a useful marker for
cancer progression [6,42,43]. We also found that CXCR4
shRNA not only significantly reduced the expression of
CXCR4, but also notably decreased phosphorylation of
CXCR4 at serine 339. Considering the findings that the
phosphorylation of CXCR4 at serine 339 may be a way to
activate CXCR4 on the cells [44], our data further confirmed
that CXCR4 shRNA could effectively inhibit CXCR4 func-
tion in IHCC cancers.
Tumorigenesis is the result of cell cycle disorganization,
leading to uncontrolled cell proliferation and cancer pro-
gression. In this study, we have demonstrated that the
blockade of CXCR4 can decrease IHCC cancer cell growth
and cell cycle by prolonging the G0–G1 cycle and redu-
cing the G2 and S phases, and inhibit tumorigenesis both
in vitro and in vivo. The Wnt/β-catenin pathway plays a
major role in intrahepatic cholangiocarcinoma cell growth,
metastasis, and cancer susceptibility [4,28-31]. Dysregula-
tion of β-catenin and other Wnt components leads to acti-
vation of Wnt target genes, including c-myc, cyclin D1,
and MMP-9 [45-47], and the enhancement of tumor for-
mation [48]. Our data showed the TOPflash luciferase ac-
tivity was sharply decreased by the inhibition of CXCR4
whereas FOPflash luciferase activity was nearly unchanged
in the β-catenin/Tcf assay. Moreover, the expression of
Wnt target genes, including β-catenin, c-myc, and MMP-
9, was markedly decreased, suggesting that the TCF-
binding activity could be effectively inhibited by CXCR4
knockdown, which may suppress theWnt/β-catenin sig-
naling and Wnt target genes expression.
Next, we analyzed the expression of invasion-related
genes Vimentin and Slug. These two genes are typical
mesenchymal markers associated with the EMT process,
which may influence carcinoma metastasis [49-54]. Our
data showed that Vimentin and Slug were downregu-
lated in CXCR4 knockdown cells, together with the de-
creased ability of invasion and migration as shown in
transwell and wound healing assays. This is consistent
with the previous report that CXCR4 could influence
EMT formation and cancer invasion [31,55-60]. How-
ever, an intriguing phenomenon was also observed in
the clinical trial of plerixafor (a CXCR4 inhibitor) as a
combined treatment with intensive chemotherapy in
heavily pre-treated relapse AML patients [61]. In the
phase II study of 46 patients, a two-fold mobilization in
leukemic blasts into the peripheral circulation was
found, which was in modest correlation with CXCR4 ex-
pression. Furthermore, in a recent phase I study of an-
other CXCR4 inhibitor LY2510924 for advanced cancer
[62], the circulating tumor cell (CTC) counts were in-
cluded as one of the study endpoints in addition to
safety, pharmacokinetics, efficacy, and pharmacodynam-
ics. In some (7/42) patients the CTC numbers wereincreased after the treatment with the CXCR4 inhibitor.
Although the significance of these studies are inconclu-
sive due to small sample sizes, these intriguing observa-
tions should prompt to investigate the mobilizing effects
of CXCR4 inhibition in tumors in more details.
Conclusions
In conclusion, the present study has shown that high
CXCR4 expression is associated with metastasis and a
poor clinical outcome of IHCC. CXCR4 appears to influ-
ence IHCC cell phenotype via the canonical Wnt pathway.
Future in vivo studies will be conducted with clinical avail-
able CXCR4 inhibitors like AMD3100 or LY2510924, and
data from these experiments could result in faster changes
of treatment for patients with IHCC.
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